Next-Generation Antibody-Drug Conjugates Make Their Mark in Breast Cancer
OncLive,
In 2013, ado-trastuzumab emtansine (T-DM1; Kadcyla) gained FDA approval for the treatment of patients with HER2-positive…
The Evolving HER2+ Metastatic Breast Cancer Landscape
Medscape,
Recent therapeutic advances in HER2-positive metastatic breast cancer (MBC) have begun to reshape the treatment landscape for…
The Evolving HER2+ Metastatic Breast Cancer Landscape
Medscape,
Recent therapeutic advances in HER2-positive metastatic breast cancer (MBC) have begun to reshape the treatment landscape for…
ADC ARX788 Gets Fast Track Status for HER2+ Metastatic Breast Cancer
Oncology Nursing News,
The FDA has granted a fast track designation to the investigational antibody-drug conjugate (ADC) ARX788 for use as a…
FDA Grants Fast Track Status to ADC ARX788 for HER2+ Metastatic Breast Cancer
OncLive,
The FDA has granted a fast track designation to the investigational antibody-drug conjugate (ADC) ARX788 for use as a…
FDA Action Moves ARX788 Forward in the Treatment of HER2-Positive Breast Cancer
Cancer Network,
Fast track designation was granted to the anti-HER2 antibody-drug conjugate ARX788 as monotherapy for the treatment of patients…